iShares U.S. Pharmaceuticals ETF
$100.96−1.96 (−1.90%)
- Expense ratio
- 0.37%
- Fund size
- $1.7B
- 1Y return
- +48.8%
- Yield · Last 12 months
- 1.39%
- Holdings
- 54
- Volume · 30D
- 0.2M sh
- NAV per share
- $102.18
- 52W range
The ETF.net IHE Grade
Score 67 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.BScore 64Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.AScore 82Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.AScore 75Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.DScore 33Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 87Category rank
Our read on IHE
BThe domestic purist of pharma funds: about 60 US drug and vaccine makers, weighted by size, no foreign names riding along. Running since 2006, it is the plain cap-weighted take on Big Pharma.
The fund seeks to track an index of U.S. companies in the pharmaceuticals sector, giving investors targeted exposure to domestic drug manufacturers and vaccine producers.
Why people hold it
- Costs 0.37% a year against a 0.57% median for pharma funds, landing within a basis point or two of the cheapest options in the group.
- Tracks the Dow Jones U.S. Select Pharmaceuticals Index: domestic drug and vaccine makers only, not the US-listed foreign pharma that PPH's index also picks up.vaneck.com
- Trading since 2006 under the iShares banner, now a billion-dollar-plus fund with moderate daily volume and quarterly distributions.
- Sits in the upper half of its pharma peer group on our review, one of the sturdier implementations of a simple, cheap, index-following mandate.
Worth knowing
- Cap weighting across about 60 names puts the largest US drug makers in the driver's seat; XPH uses modified equal weight to spread dollars across large, mid and small caps.ssga.com
- Pharma only. No biotech, devices or insurers, and the fund is non-diversified, making it a narrow slice of health care.ishares.com
- The 0.37% fee undercuts the category median but not the floor: XPH at 0.35% and PPH at 0.36% shade it slightly.
IHE Holdings
- Stocks
- 54
- 78%
- LLY
Sectors
- Health Care100.0%
Geography
- United States96.14%
- Ireland3.86%
IHE Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IHE |
|---|---|
| Year to date | +22.4% |
| 1 month | −3.4% |
| 3 months | +11.4% |
| 1 year | +48.8% |
| 3 years | +21.6% |
| 5 years | +12.7% |
| 10 years | +8.7% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IHE |
|---|---|---|
| 2026 YTD | +22.4% | |
| 2025 | +31.7% | |
| 2024 | +8.1% | |
| 2023 | +1.1% | |
| 2022 | −4.9% | |
| 2021 | +13.1% | |
| 2020 | +13.7% |
IHE in the news
ETF.net Research hasn’t filed on IHE yet — coverage lands here as it’s written.
IHE Dividends
- 1.39%
- $1.43
- $0.28 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Sep 15, 2026 | Sep 18, 2026 | $0.28 |
| Jun 15, 2026 | Jun 18, 2026 | $0.28 |
| Mar 17, 2026 | Mar 20, 2026 | $0.28 |
| Dec 16, 2025 | Dec 19, 2025 | $0.59 |
| Sep 16, 2025 | Sep 19, 2025 | $0.31 |
| Jun 16, 2025 | Jun 20, 2025 | $0.31 |
| Mar 18, 2025 | Mar 21, 2025 | $0.29 |
| Dec 17, 2024 | Dec 20, 2024 | $0.21 |
| Sep 25, 2024 | Sep 30, 2024 | $0.36 |
| Jun 11, 2024 | Jun 17, 2024 | $0.29 |
| Mar 21, 2024 | Mar 27, 2024 | $0.28 |
| Dec 20, 2023 | Dec 27, 2023 | $0.13 |
IHE Risk
- 15.8%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.94
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −16.0%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.50
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IHE Cost
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
3 of the 9 Pharma & Therapeutics funds charge less.